GO
Loading...

Enter multiple symbols separated by commas

Novartis AG

More

  • Core Inflation to Drift Lower: JPMorgan's Kasman Tuesday, 17 Nov 2009 | 1:11 PM ET

    U.S. producer prices rose more slowly than expected in October despite a rebound in food and energy costs, according to a report on Tuesday. Bruce Kasman, chief U.S. economist at JPMorgan, shared his view.

  • Merck’s Mega-Monday Morning Tuesday, 10 Nov 2009 | 10:26 AM ET
    Health Care Reform

    Many analysts, lobbyists and industry executives have been saying for months that healthcare reform would probably end up being a net positive for the drug companies.

  • Trading The Globe: 3 Hot China Plays Wednesday, 4 Nov 2009 | 5:43 PM ET

    You know that Tim Seymour is bullish on China but now he’s got three new reasons to get long. Should you follow any of them?

  • Still Waiting On Witty Wednesday, 28 Oct 2009 | 11:15 AM ET
    gsk_logo.jpg

    GlaxoSmithKline is one of the handful of drug companies on the front lines of the fight against the flu. In fact, it is the only company that has products on both sides. GSK makes a vaccine and an antiviral. In the third quarter, GSK today reported that it sold nearly $300 million worth of the inhalable flu-fighter Relenza. That’s a more than 10-fold increase from a year ago. And CEO Andrew Witty reportedly forecast around $1.6 billion worth of flu shot sales in the fourth quarter.

  • Dow Ends Up 1.3%, Led by Travelers, MMM Thursday, 22 Oct 2009 | 5:35 PM ET

    Stocks advanced Thursday as investors seemed to focus more on some big-name earnings beats and a rise in leading indicators instead of a disappointing jobless report. Travelers and MMM led the Dow.

  • No Big H1N1 Shipments Until December: Novartis Thursday, 22 Oct 2009 | 2:26 PM ET

    Swiss drug giant Novartis says it has redeployed 300 workers from other divisions into its vaccines unit to meet what Chairman and CEO Dr. Daniel Vasella calls the "huge demand" for H1N1 shots.

  • Dow Rises, Led by Travelers, MMM Thursday, 22 Oct 2009 | 2:13 PM ET

    Stocks advanced Thursday as investors seemed to focus more on some big-name earnings beats and a rise in leading indicators instead of a disappointing jobless report.

  • Dow Rebounds After Leading Indicators Thursday, 22 Oct 2009 | 10:39 AM ET

    Stocks slipped Thursday as investors weighed a disappointing jobless-claims report and some encouraging earnings reports.

  • Futures Fall as Earnings Season Continues Thursday, 22 Oct 2009 | 6:04 AM ET

    Earnings continue to come in largely above expectations, but other factors are waylaying the stock market's recent advances - ranging from Walmart's price cuts to analyst Richard Bove's downgrade of Wells Fargo to rising oil prices. 

  • Big BioPharma Earnings Opportunities Wednesday, 21 Oct 2009 | 5:37 PM ET

    With Amgen dropping after hours and Merck, Celgene and others reporting earnings on Thursday, how should you game health care?

  • Amgen's Party Pooper Monday, 19 Oct 2009 | 12:27 PM ET
    Amgen

    In case you weren't aware, tomorrow is "World Osteoporosis Day" or WOD, for short, as the International Osteoporosis Foundation hilariously refers to it, but biotech Amgen won't be celebrating the occasion.

  • H1N1 Shots Are Here: Sign Me Up Wednesday, 14 Oct 2009 | 12:31 PM ET
    swine_flu_needle_200.jpg

    This Friday the CDC is expected to start giving weekly updates on where and how much H1N1 vaccine has been shipped. I'm curious what the demand will truly turn out to be. Some people are growing concerned about the increasing number of pediatric deaths from H1N1 and may rush to get their kids and themselves vaccinated. Others are afraid of or paranoid about the vaccine.

  • Novartis Vindicates Vanda Tuesday, 13 Oct 2009 | 3:58 PM ET
    Novartis Headquarters

    Vanda Pharmaceuticals may go down in industry history as one of the most remarkable turnaround stories.

  • JNJ Facing a 'Tough Period': Medical Tech Analyst Tuesday, 13 Oct 2009 | 11:56 AM ET

    Dow component Johnson & Johnson—the first major health care company to report earnings this quarter—posted weaker-than-expected quarterly revenue on Tuesday. Mike Weinstein, managing director and senior medical technology analyst at JPMorgan, offered his analysis of JNJ.

  • Novartis' Flu Shot Across The Bow Tuesday, 6 Oct 2009 | 1:23 PM ET
    Pharmacist wearing face mask

    Yesterday and today thousands of kids and healthcare workers around the country started getting AstraZeneca's H1N1 FluMist, the vaccine that's sprayed into the nose. The first shots from Novartis and Sanofi-Aventis may be available later this week. GlaxoSmithKline and Baxter are still waiting for the FDA to approve their vaccines.

  • Biotechs Gain on Flu Vaccine Hopes Monday, 5 Oct 2009 | 12:06 PM ET

    The CDC announced today that healthcare workers in Tennessee and Indiana would be amongst the first to get swine flu vaccinations.  The outbreak of the H1N1 swine flu virus has sadly killed over 3,900 peope per a report by the World Health Organization (WHO) on September 25th.  At the same time the race to battle the pandemic has propped up the shares of biotech companies that promise solutions.

  • H1N1 Vaccine Is Top Flu Concern For U.S. Businesses Wednesday, 30 Sep 2009 | 7:36 AM ET
    New York Public Information Campaign Warns of Swine Flu

    The number-one H1N1 flu concern among U.S. businesses is the availability of a vaccine for employees, according to a new survey by the Business Roundtable.

  • Major US Firms Draw Up Emergency Plans for Swine Flu Tuesday, 29 Sep 2009 | 2:28 PM ET
    flu_outbreak.jpg

    Major US companies are bracing for a potentially stronger strain of swine flu this year that could threaten the nation's already fragile economic recovery.

  • Do Drugs And Tweets Mix? Wednesday, 23 Sep 2009 | 2:50 PM ET
    Twitter

    The drug biz is abuzz over social media. It's the new frontier. For a lot of PR and corporate communications teams it's all about new media and social media. Some biopharmas, big and small, now have directors of social media. Most are still trying to find their way, but the Food and Drug Administration may soon direct them.

  • Pros Say: Expect More 'Sell on News' Activity Thursday, 3 Sep 2009 | 10:08 AM ET
    This Day 1 Year Ago - A CNBC Special Report - See Complete Coverage

    So far, it hasn't been a September to remember on Wall Street. With three days in the books, the month is living up to its historic billing as the worst month of the year for stock investors, though Wednesday's losses were relatively small. Read and listen to what the pros had to say...